BUSINESS
    AbbVie’s Japan Sales in 2018 Double on Maviret Boon
    May 23, 2019
    AbbVie’s Japan revenue rocketed 104% to 172.6 billion yen in 2018, buoyed by its hepatitis C drug Maviret (glecaprevir + pibrentasvir), outperforming the double-digit growth pledged last year by country helmsman James Feliciano with an…

    LATEST

    Trelegy Hits Japan Shelves, Novartis Starts Accepting Orders for Kymriah
    May 23, 2019
    A slew of new drugs joined the NHI reimbursement price list on May 22, with GlaxoSmithKline’s inhaler COPD treatment Trelegy Ellipta (fluticasone furoate + umeclidinium + vilanterol) making its Japan debut. Meanwhile, Novartis Pharma started taking orders for its CAR-T…
    MHLW Approves Entyvio’s Crohn’s Disease Indication and More
    May 23, 2019
    The Ministry of Health, Labor and Welfare (MHLW) on May 22 approved new indications and dosages for six drugs including Takeda Pharmaceutical’s inflammatory bowel disease medicine Entyvio (vedolizumab) for the treatment of Crohn’s disease (CD).Entyvio earned approval for use in…
    Hodanren Renews Call for Transparent Pricing for Kymriah
    May 23, 2019
    The Japanese Medical and Dental Practitioners for the Improvement of Medical Care (Hodanren) reiterated its push for more transparency in the pricing of Novartis Pharma’s CAR-T cell therapy Kymriah (tisagenlecleucel) in a statement issued on May 22 in conjunction with…

    INTERVIEW

    As New Era Dawns, Eisai CEO Says Pharma Could Be True Winner of 4th Industrial Revolution
    By Yoshinori Sagehashi

    As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…

    TRENDS

    Cancer Drugs Underpin Big Pharmas’ Japan Revenue in 2018
    By Rejii Anasako

    While grappling with sluggish revenues in Japan last year amid 1.7% negative market growth as put by IQVIA, mega pharma companies saw their upbeat oncology franchises increasingly buttress their businesses in the country, helping them soften the blows from generic…

    Upside in Decelerating Gx Arena

    In Authorized Generic Spree, Daiichi Sankyo Espha Focuses More on “Popularization” than “Sales” When It Comes to Cancer AGs
    By Takashi Ebisawa and Tatsuya Otsuka

    Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

    My Viewpoint on CEA

    Ensuring Patient Access Was MHLW’s Top Priority for CEA Scheme: Policy Planning Director
    By Yoshinori Sagehashi

    Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

    COMMENTARY

    Cell Therapy Makers Working to Stand Out from Rivals by Reducing Burdens on Hospitals
    By Takashi Ebisawa

    Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…

    HTA Debates in 2018-2019

    Japan to Roll Out Cost-Effectiveness Assessment Scheme in April

    Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA